Home

ABOUT

Editorial

PRESS RELEASES

MEDICAL DEVICE NEWS MAGAZINE

A DIGITAL PUBLICATION FOR THE PRACTICING MEDICAL SPECIALIST, INDUSTRY EXECUTIVE AND INVESTOR

SUBSCRIBE

Market Reports

FDA

Executives

Funding

Non Profits

Hospitals

Acquisitions

Health

Biotechnology News Magazine

HomeMEDICAL DEVICESFirst Implants of PROPEL® Contour in Patients with Chronic Rhinosinusitis Following Frontal...

First Implants of PROPEL® Contour in Patients with Chronic Rhinosinusitis Following Frontal Sinus Surgery in Europe

Intersect ENT®, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that Helios Dr. Horst Schmidt Kliniken Wiesbaden in Germany was the first hospital outside the United States to offer the Company’s PROPEL® Contour (mometasone furoate) sinus implant following functional endoscopic sinus surgery (FESS). FESS is used to treat chronic rhinosinusitis, a persistent inflammation of the sinuses that can be debilitating to patients.

Intersect ENT’s PROPEL Contour is a drug-eluting, bioabsorbable sinus implant that is placed in the frontal sinus (between the eyebrows) following sinus surgery. PROPEL Contour incorporates a unique hourglass design that conforms to the sinus openings that delivers an advanced corticosteroid with anti-inflammatory properties and mechanical support to help improve surgical outcomes. PROPEL Contour is clinically proven to reduce the need for additional interventions (surgical treatments and/or oral steroids) after sinus surgery by 65 percent.1 PROPEL Contour is the third localized drug delivery implant (inclusive of PROPEL and PROPEL Mini), completing the PROPEL family of drug-eluting, bioabsorbable implants now available to ENT specialists in select EU countries.

“After treating my first two patients with PROPEL Contour post-functional endoscopic sinus surgery in August 2021, I was pleased with the design of the PROPEL Contour sinus implant for patients with variable frontal sinus openings that are suffering from chronic rhinosinusitis,” said Prof. Dr. Jan Gosepath, Chairman, Department of Otolaryngology, Head and Neck Surgery, Helios HSK Wiesbaden and Medical Director, Helios Dr. Horst Schmidt Privatklinik Wiesbaden. “With this implant, the surgically enlarged sinus opening can be maintained, and the steroid can be delivered directly to the site where it is needed most to improve postoperative outcomes. At 4-weeks follow-up, both patients showed excellent wound healing, which is what I like to see. Another benefit of the PROPEL Contour implant is that it does not need to be removed and will dissolve after approximately 4-6 weeks.”

spot_img

DON'T MISS

United States Cardiovascular Devices Market 2021-2027

United States Cardiovascular Devices Market is projected to reach US$ 39.98 Billion by 2027 from US$ 25.34 Billion in 2020, growing with a CAGR of 6.73%

Global Cerebrospinal Fluid Drainage Catheter Market (2021 to 2027) – by Application, Type and Regional Outlook

The Global Cerebrospinal Fluid Drainage Catheter Market size is expected to reach $402.6 Million by 2027, rising at a market growth of 8.6% CAGR during the forecast period. For the treatment of hydrocephalus, placement of cerebral spinal fluid (CSF) shunt systems is becoming a common medical and life-saving procedure for the majority of the patients.

United States Insulin Delivery Devices Market Report 2021

This new report provides an in-depth assessment of the U.S insulin delivery devices market dynamics, opportunities, future road-map, competitive landscape and discusses major trends.

Global $45 Billion Endoscopy Market Insights & Forecasts to 2025

The global endoscopy market is predicted to reach US$45.28 billion in 2025, growing, at a CAGR of 7.50%, for the duration spanning 2021-2025.

Our Sister Publication: Biotechnology News Magazine

By using this website you agree to accept Medical Device News Magazine Privacy Policy

Join Our Email List & Receive a Recap of the Week's News!